Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
XeriSol glucagon · 1 trial · 1 indication
Assess the percent of time that the Dexcom G5 or G6 reported sensor glucose values less than 70 mg/dl using Dexcom sensor across all three arms.
| Arm | Type | Description |
|---|---|---|
| Dual Hormone Closed-loop Arm | EXPERIMENTAL | Subjects will undergo a 76 hour study with 9 hours inpatient and 67 hours outpatient using the closed-loop artificial pancreas controller in dual hormone mode and XeriSol glucagon to manage blood sugar that includes an exercise detection component that includes a reduction in insulin delivery and an increase in glucagon delivery upon detection. |
| Single Hormone Closed-loop Arm | EXPERIMENTAL | Subjects will undergo a 76 hour study with 9 hours inpatient and 67 hours outpatient using the closed-loop artificial pancreas controller in single hormone mode to manage blood sugar that includes an exercise detection component that includes a reduction in insulin delivery upon detection. |
| Predictive Low Glucose Suspend Arm | EXPERIMENTAL | Subjects will undergo a 76 hour study with 9 hours inpatient and 67 hours outpatient using the closed-loop artificial pancreas controller in predictive low glucose suspend mode. The system will run through the closed-loop system but will utilize the patient's optimized basal rates, correction factors and carb ratios as they would normally run on their own insulin pump. But the mode will have the additional safety net of the pump suspending insulin when it predicts a hypoglycemic event. |
| Name | Type | Description |
|---|---|---|
| Artificial Pancreas Controller in Dual Hormone Mode | DEVICE | The artificial pancreas controller contains an algorithm for managing blood glucose in people with type 1 diabetes which includes an exercise detection component. The algorithm has 3 modes: a single hormone closed-loop insulin only mode, a dual-hormone closed-loop insulin and glucagon mode and an insulin only mode with predictive low glucose suspend. The Closed-loop Artificial Pancreas Controller includes insulin and glucagon delivery algorithm implemented on a smart phone, utilizing sensor glucose values from a Dexcom G5 sensor and sending delivery commands to two Omnipod insulin pumps, one filled with insulin and one with glucagon. |
| Artificial Pancreas Controller in Single Hormone Mode | DEVICE | The artificial pancreas controller contains an algorithm for managing blood glucose in people with type 1 diabetes which includes an exercise detection component. The new algorithm will have 3 modes: a single hormone closed-loop insulin only mode, a dual-hormone closed-loop insulin and glucagon mode and an insulin only mode with predictive low glucose suspend. The Closed-loop Artificial Pancreas Controller includes insulin delivery algorithm implemented on a smart phone, utilizing sensor glucose values from a Dexcom G5 sensor and sending delivery commands to one Omnipod pump filled with insulin. |
| Artificial Pancreas Controller in Predictive Low Glucose Suspend Mode | DEVICE | The artificial pancreas controller contains an algorithm for managing blood glucose in people with type 1 diabetes which includes an exercise detection component. The new algorithm will have 3 modes: a single hormone closed-loop insulin only mode, a dual-hormone closed-loop insulin and glucagon mode and an insulin only mode with predictive low glucose suspend. The Closed-loop Artificial Pancreas Controller includes insulin delivery algorithm implemented on a smart phone, utilizing sensor glucose values from a Dexcom G5 sensor and sending delivery commands to one Omnipod insulin pump filled with insulin. |
| XeriSol glucagon | DRUG | XeriSol glucagon is an investigational drug that is a stable, soluble liquid glucagon formulation that can be injected or administered through an insulin pump. XeriSol glucagon will be used to fill the Omnipod to deliver glucagon for the Artificial Pancreas Controller in Dual Hormone mode. |
Inclusion Criteria: * Diagnosis of type 1 diabetes mellitus for at least 1 year. * Male or female subjects 21-50 years of age. * Physically willing and able to perform 45 min of exercise. * Current use of an insulin pump. * Lives with another person age 18 or older who will be present while subject...
XeriSol glucagon is an investigational small molecule being developed for Type 1 diabetes. It is designed for use in a closed-loop system to manage blood glucose levels. The drug is currently in Phase 1 clinical development and is not yet approved by the FDA.
XeriSol glucagon is a glucagon formulation, meaning it is designed to deliver the hormone glucagon. Glucagon works to raise blood glucose levels by promoting the release of glucose from the liver, counteracting the effects of insulin. This mechanism is relevant for managing hypoglycemia in Type 1 diabetes.
XeriSol glucagon is being developed by Xeris Biopharma Holdings, Inc., a biopharmaceutical company traded on the Nasdaq under the ticker symbol XERS. The company is advancing the drug through clinical trials for use in Type 1 diabetes.
XeriSol glucagon is in Phase 1 clinical development. It is an investigational drug and has not received FDA approval. The drug is still in the early stages of clinical testing, with one completed Phase 1 trial.
XeriSol glucagon has one completed Phase 1 trial, NCT03424044, titled "Three Way Crossover Closed Loop Study With Xeris Glucagon." The study enrolled 23 participants with Type 1 diabetes in the United States and was a controlled, randomized trial, though not double-blinded.
XeriSol glucagon is a formulation of the hormone glucagon, developed by Xeris Biopharma. It is designed to deliver glucagon in a stable, injectable form for use in Type 1 diabetes management. The drug is being studied for its ability to raise blood glucose in a closed-loop system.